The samples with the highest ERVmap_1248 expression also had the highest inflammatory signature score (based on the expression of CD8A, STAT1, LAG3 and CD274), which predicts response to checkpoint inhibitors in the CheckMate743 trial, where previously untreated mesothelioma patients received either the immune checkpoint inhibitors anti-PD1 and anti-CTLA-4 or chemotherapy [91]. The gene discussed is CD274; the disease is mesothelioma.